2,231 results on '"Dinney, Colin"'
Search Results
2. Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer
3. DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial
4. Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis
5. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
6. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract
7. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy
8. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
9. Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer
10. Lentiviral interferon: A novel method for gene therapy in bladder cancer
11. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes
12. Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model.
13. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma
14. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin
15. The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward
16. MP16-07 URINARY MINIMAL RESIDUAL DISEASE DETECTION PREDICTS RECURRENCE IN BCG-UNRESPONSIVE NIMBC AND QUANTIFIES MOLECULAR RESPONSE TO NADOFARAGENE FIRADENOVEC
17. MP65-06 NOVEL COMBINATION THERAPY USING INTERFERON GENE THERAPY AND GEMCITABINE IN MURINE BLADDER CANCER CELL LINES
18. PD48-01 EFFICACY OF NADOFARAGENE FIRADENOVEC-VNCG FOR PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: FINAL RESULTS FROM A PHASE 3 TRIAL
19. MP16-08 CHALLENGING THE PARADIGM OF “BCG UNRESPONSIVE” BLADDER CANCER: DOES ADDITIONAL BCG HAVE AN EFFECT?
20. MP65-12 FOXF1: A NOVEL REGULATOR OF METASTASIS IN UROTHELIAL CARCINOMA OF THE BLADDER
21. PD30-08 ELUCIDATING THE RESPONSE RATES TO CONTINUED BACILLUS CALMETTE-GUERIN (BCG) IN PATIENTS WITH BCG EXPOSED BLADDER CANCER: IMPLICATIONS FOR CLINICAL TRIAL DESIGN
22. MP65-05 SINGLE-CELL RNA SEQUENCING IDENTIFIES CHANGES IN TUMOR MICROENVIRONMENT INDUCED BY INTERFERON α GENE THERAPY IN MURINE BLADDER CANCER MODEL
23. What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs
24. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer
25. Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center
26. Unique somatic variants in DNA from urine exosomes of individuals with bladder cancer
27. Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis
28. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer
29. Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes
30. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
31. Intravesical Gene Therapy
32. Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context
33. Inferring Bladder Cancer Evolution from Mucosal Field Effects by Whole-Organ Spatial Mutational, Proteomic, and Metabolomic Mapping
34. NOVEL COMBINATION THERAPY USING INTERFERON GENE THERAPY AND GEMCITABINE IN MURINE BLADDER CANCER CELL LINES
35. FOXF1: A NOVEL REGULATOR OF METASTASIS IN UROTHELIAL CARCINOMA OF THE BLADDER
36. MORPHOLOGICAL PROGRESSION IN RELAPSING PATIENTS WITH SMALL CELL BLADDER CANCER
37. EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL
38. SINGLE-CELL RNA SEQUENCING ANALYSIS IDENTIFIES CHANGES IN TUMOR MICROENVIRONMENT INDUCED BY INTERFERON α GENE THERAPY IN A MURINE MODEL OF BLADDER CANCER
39. Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy
40. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry
41. Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort
42. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
43. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
44. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship
45. Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test
46. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer
47. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign
48. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis
49. Oncolytic Virotherapy Combined with Nivolumab Elicits Complete Responses in Muscle-Invasive Bladder Cancer in Association with the Formation of Tertiary Lymphoid Structures
50. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.